AOD9604 is a synthetic peptide made from a small fragment of human growth hormone. Specifically, it replicates amino acids 176 through 191 from the tail end of the growth hormone molecule, which is the region responsible for fat metabolism. The idea behind it is simple: isolate the fat-burning portion of growth hormone without triggering the side effects that come with the full hormone, like insulin resistance or abnormal tissue growth.
How AOD9604 Relates to Growth Hormone
Human growth hormone is a large protein with many functions, from stimulating muscle growth to regulating blood sugar and body composition. AOD9604 copies only a 16-amino-acid stretch from the bottom of that protein. This fragment appears to retain the ability to influence fat cells while lacking the parts that drive growth-promoting effects elsewhere in the body.
In human clinical trials, AOD9604 had no effect on IGF-1 levels, the downstream signal responsible for most of growth hormone’s tissue-building (and potentially harmful) actions. It also showed no negative impact on carbohydrate metabolism or insulin sensitivity, both common concerns with full-length growth hormone therapy. In safety studies, the peptide’s side effect profile was indistinguishable from placebo, and no serious adverse events related to the compound were reported across multiple trials.
How It Works in the Body
AOD9604’s primary mechanism involves fat cell signaling. Research in obese mice found that the peptide increases the expression of a specific receptor on fat cells called the beta-3 adrenergic receptor. This receptor plays a central role in breaking down stored fat and converting it into energy. In obese animals, levels of this receptor are suppressed. Both full-length growth hormone and AOD9604 were able to restore that receptor’s activity to levels seen in lean animals.
Interestingly, the relationship is indirect. When researchers tested AOD9604 in mice that completely lacked the beta-3 receptor, the long-term fat loss effect disappeared, confirming the receptor’s importance. But in short-term experiments, the peptide still managed to increase energy expenditure and fat burning even in those receptor-deficient mice, suggesting it has at least one additional pathway it can act through. The overall picture is that AOD9604 enhances the body’s existing fat-burning machinery rather than working through a completely novel mechanism.
What the Clinical Trials Showed
AOD9604 went through several phases of human testing. Early trials used intravenous doses in healthy men at ranges from 25 to 400 micrograms per kilogram of body weight. Later studies shifted to oral capsules and tablets, with doses ranging from 0.25 milligrams to 54 milligrams per day. The largest trial enrolled 534 clinically obese adults (BMI of 30 to 45) who took daily oral doses of 0.25, 0.5, or 1 milligram for 24 weeks. Another study of 300 obese participants tested higher doses of 1 to 30 milligrams daily for 12 weeks.
Safety was consistently favorable across all these studies. No participants withdrew due to side effects related to AOD9604, and the compound produced none of the metabolic disruptions associated with growth hormone therapy. However, the weight loss results were less impressive than the animal data had predicted. The peptide never secured regulatory approval as an obesity treatment, and no major pharmaceutical company has carried it further through the drug approval process for that purpose.
Cartilage and Joint Research
More recently, AOD9604 has attracted attention in regenerative medicine. In a rabbit study using a model of knee osteoarthritis, intra-articular injections of AOD9604 enhanced cartilage regeneration. The peptide is now grouped alongside other compounds being studied for joint repair and bone health, though this research is still in early stages and has not been validated in large human trials.
How Quickly It Breaks Down
AOD9604 is cleared from the body rapidly. In animal studies using intravenous dosing, the peptide’s half-life was approximately three minutes, meaning it disappears from the bloodstream almost immediately. When given orally, blood levels peaked around 60 minutes after dosing, suggesting the gut absorbs it reasonably well, though the exact oral bioavailability has never been clearly established. The FDA has noted that no human pharmacokinetic studies (measuring how the drug moves through and is processed by the body) have been identified for any route of administration.
Regulatory and Sports Status
AOD9604 is not an FDA-approved drug. The FDA evaluated it for potential inclusion on a list of bulk drug substances that compounding pharmacies could use, but the peptide’s lack of robust human efficacy data and unclear pharmacokinetics have kept it in a regulatory gray area. It is available through some compounding pharmacies and wellness clinics, typically as a subcutaneous injection, though the quality and consistency of these products can vary significantly.
For athletes, the compound is clearly off-limits. The World Anti-Doping Agency lists AOD9604 as a prohibited substance at all times, both in and out of competition. It falls under the category of growth hormone fragments alongside the closely related peptide hGH 176-191, and it is classified as a non-specified substance, meaning violations carry the most severe penalties.